Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNSROTCMKTS:POSCNASDAQ:RCELNYSEAMERICAN:STXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNSRLENSAR$13.59+0.2%$13.94$3.50▼$17.31$160.14M0.5678,891 shs86,350 shsPOSCPositron$1.58-5.7%$1.59$0.88▼$2.94$49.46M0.4424,198 shs8,615 shsRCELAVITA Medical$6.14-2.3%$8.41$6.13▼$14.16$162.31M1.74179,787 shs73,932 shsSTXSStereotaxis$2.11+1.9%$1.91$1.54▼$2.72$178.78M1.54436,687 shs142,247 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNSRLENSAR0.00%-3.83%-2.52%+44.10%+223.63%POSCPositron0.00%+5.33%+5.33%-9.20%+29.51%RCELAVITA Medical0.00%-6.82%-37.64%-33.83%-22.47%STXSStereotaxis0.00%-0.96%+5.08%-4.61%+4.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLNSRLENSAR1.2055 of 5 stars2.05.00.00.00.62.50.0POSCPositronN/AN/AN/AN/AN/AN/AN/AN/ARCELAVITA Medical1.2836 of 5 stars3.40.00.00.03.10.00.6STXSStereotaxis0.587 of 5 stars0.02.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNSRLENSAR 2.00Hold$15.0010.38% UpsidePOSCPositron 0.00N/AN/AN/ARCELAVITA Medical 2.75Moderate Buy$17.25181.13% UpsideSTXSStereotaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest POSC, STXS, RCEL, and LNSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/4/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/24/2025LNSRLENSARBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $15.003/18/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.002/28/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNSRLENSAR$57.07M2.81N/AN/A$2.97 per share4.58POSCPositron$740K66.84N/AN/A($0.04) per share-39.50RCELAVITA Medical$71.66M2.26N/AN/A$0.17 per share36.09STXSStereotaxis$26.77M6.68N/AN/A$0.20 per share10.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNSRLENSAR-$14.38M-$4.85N/A∞N/A-34.03%-49.02%-21.12%8/6/2025 (Estimated)POSCPositron-$1.64M-$0.08N/A∞N/A-278.51%N/A-88.40%N/ARCELAVITA Medical-$61.85M-$2.19N/AN/AN/A-96.26%-337.91%-71.50%8/14/2025 (Estimated)STXSStereotaxis-$20.71M-$0.28N/AN/AN/A-85.79%-162.54%-51.26%8/11/2025 (Estimated)Latest POSC, STXS, RCEL, and LNSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025POSCPositronN/A-$0.05N/A-$0.05N/A$0.12 million5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million5/8/2025Q1 2025RCELAVITA Medical-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 million2/27/2025Q4 2024LNSRLENSAR-$0.21-$1.61-$1.40-$1.61$14.95 million$16.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNSRLENSARN/AN/AN/AN/AN/APOSCPositronN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNSRLENSARN/A3.372.10POSCPositronN/A0.620.12RCELAVITA Medical9.392.832.47STXSStereotaxisN/A1.390.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNSRLENSAR40.15%POSCPositronN/ARCELAVITA Medical27.66%STXSStereotaxis45.35%Insider OwnershipCompanyInsider OwnershipLNSRLENSAR38.52%POSCPositron17.20%RCELAVITA Medical1.82%STXSStereotaxis18.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNSRLENSAR11011.79 million7.14 millionOptionablePOSCPositron2031.31 million22.61 millionNot OptionableRCELAVITA Medical13026.44 million25.74 millionOptionableSTXSStereotaxis13084.73 million69.04 millionNot OptionablePOSC, STXS, RCEL, and LNSR HeadlinesRecent News About These CompaniesStereotaxis shareholders approve board nominees and auditorMay 21, 2025 | investing.comEarnings call transcript: Stereotaxis Q1 2025 reports stable EPS, revenue growthMay 14, 2025 | uk.investing.comStereotaxis, Inc. (AMEX:STXS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comLagoda Investment Management L.P. Purchases 295,700 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS)May 14, 2025 | marketbeat.comStereotaxis, Inc.: Stereotaxis Reports 2025 First Quarter Financial ResultsMay 14, 2025 | finanznachrichten.deStereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...May 14, 2025 | finance.yahoo.comStereotaxis reiterates double-digit revenue growth outlook for 2025 as recurring revenue and MAGiC adoption rampMay 13, 2025 | msn.comStereotaxis, Inc. (STXS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comStereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comStereotaxis Reports 2025 First Quarter Financial ResultsMay 12, 2025 | globenewswire.comStereotaxis Inc (STXS) Q1 2025: Everything You Need to Know Ahead of EarningsMay 10, 2025 | finance.yahoo.comStereotaxis (STXS) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comStereotaxis to Showcase GenesisX Robotic System at Heart Rhythm Symposium 2025April 23, 2025 | nasdaq.comStereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025April 22, 2025 | globenewswire.comStereotaxis to feature first-ever live demo of GenesisX Robotic SystemApril 21, 2025 | markets.businessinsider.comStereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025April 21, 2025 | globenewswire.comStereotaxis management to meet virtually with Lake StreetApril 1, 2025 | markets.businessinsider.com3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025March 26, 2025 | zacks.comNvidia’s Support Boosts Stereotaxis (STXS) in Advancing Robotic SurgeryMarch 24, 2025 | msn.comStereotaxis gains support from NVIDIA for AI roboticsMarch 21, 2025 | uk.investing.comStereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?March 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?UPS Stock Forecast: Rebound Underway for United Parcel Service?By Thomas Hughes | May 4, 2025View UPS Stock Forecast: Rebound Underway for United Parcel Service?POSC, STXS, RCEL, and LNSR Company DescriptionsLENSAR NASDAQ:LNSR$13.59 +0.03 (+0.22%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Positron OTCMKTS:POSC$1.58 -0.10 (-5.67%) As of 05/23/2025 12:05 PM EasternPositron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.AVITA Medical NASDAQ:RCEL$6.14 -0.14 (-2.29%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.Stereotaxis NYSEAMERICAN:STXS$2.11 +0.04 (+1.93%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Scores First $1 Billion Contract; Is It Priced In? Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down its Tech and Outlook MarketBeat Week in Review – 05/19 - 05/23 Workday Stock Price Implosion: An Automatic Buy for AI Investors Can Ross Stores Be the Safety Cushion In Retail Stocks? MercadoLibre Is Soaring—Should You Wait for a Better Entry? Trade Desk Silences Critics; Recovery Looks Poised to Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
